Efficacy Study of IZN-6D4 Gel for the Treatment of Diabetic Foot Ulcers

Izun Pharma

Status and phase: Completed; Phase 2

Conditions: Diabetic Foot Ulcer

Treatments: Other: Placebo hydrogel; Drug: IZN-6D4 Gel

Study type: Interventional

Funder types: Industry

Identifiers

NCT01427569

IWH-DFU-101-IL

Details and patient eligibility

About

The purpose of this study is to determine if topical application of a hydrogel that contains plant extracts will improve healing of diabetic foot ulcers when compared to treatment with a hydrogel alone.

Full description

This is a multi center, double-blind, randomized, placebo-controlled trial. A total of 80 patients will be randomized according to a 1: 1 randomization schedule. To participate in the trial, patients must have a current Diabetic Foot Ulcer (DFU) for between 60 days to 2 years at the screening visit. In the 2-week period between screening and baseline visit, the patient's DFU must not have healed by 30% or more, in wound area, while being treated with SWT twice a week during this screening period.

During the treatment period of 4 weeks all patients will be examined on a weekly basis by the site staff. Treatment with SWT plus the study gel (IZN-6D4 Gel or placebo gel) (including any necessary debridement) will be administered at these weekly visits. In addition, the patient or caregiver will be trained to perform SWT plus the study treatment at home once midweek between visits.

Enrollment: 82 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Current diagnosis of diabetes mellitus type 1 or 2
• Foot ulcer Wagner grade 1 or 2
• Ulcer between 1 square cm and 8 square cm present for at least 60 days and not more than two years
• HgbA1C less than 10%
• Able to comply with all procedures

Exclusion criteria

• Wound area decrease of greater than 30% between screening and baseline visits
• Gangrene on any part of the affected foot
• Pregnancy or lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

82 participants in 2 patient groups, including a placebo group

IZN-6D4 Gel

Experimental group

Description:

patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel

Treatment:

Drug: IZN-6D4 Gel

Placebo Hydrogel

Placebo Comparator group

Description:

patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4

Treatment:

Other: Placebo hydrogel